Dermatology Drugs MGR 2017
July 2017
125
About the Report
About the Report
Dermatology drugs market include medications that are used for the treatment of skin conditions such as dermatitis (including eczema), rosacea, hyperhidrosis, androgenic alopecia, onychomycosis, hair loss, acne, immune disorders (including psoriasis), microbial infections (bacterial, fungal, and viral), vascular and pigmented lesion removal, common warts, seborrheic keratosis, and other skin diseases.
These drugs can be sold as OTC as well as prescription drugs. Some of the major OTC drugs include Differin, Lamisil, Monistat, and Abreva. Some of the major dermatology prescription drugs include Humira, guselkumab, Abilify, Sovaldi, Harvoni, and Nexium.
The global dermatology drugs market was estimated to be around $31 billion as of 2016. The dermatology drugs market made up around 3% of the overall pharmaceuticals market in 2016. The dermatology drugs market was the thirteenth largest market in the global pharmaceutical market in 2016.
Increase in Mergers and Acquisitions Activity
The market has witnessed multiple strategic initiatives in the recent years. Top companies in the dermatology drugs market strategically acquired start-ups and mid-sized companies to broaden products and services. For instance, LEO Pharma, a Denmark-based company acquired the global dermatology business of Astellas Pharma for $725 million. This deal allows LEO to increase its product portfolio with Astellas Pharma's dermatology products include Protopic, Locoid, Locobase and Zineryt. Also Piramal Enterprises Ltd, an Indian based company acquired over-the-counter dermatology brand Caladryl in India from Valeant Pharmaceuticals Inc. Through this acquisition Piramal widen its consumer products portfolio in the skin care segment. The process of consolidation in the industry is boosting growth by increasing the marketing and distribution power of dermatology drug companies.
The Dermatology Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global dermatology drugs sector.
Reasons to Purchase
Outperform competitors using accurate up to date demand-side dynamics information.
Identify growth segments for investment.
Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
Create regional and country strategies on the basis of local data and analysis.
Stay abreast of the latest customer and market research findings
Benchmark performance against key competitors.
Develop strategies based on likely future developments.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Gain a global perspective on the development of the market.
Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the dermatology drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dermatology drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
Market segmentations break down market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
The dermatology drugs market section of the report gives context. It compares the dermatology drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Dermatology Drugs Indicators Comparison.
The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.
Scope
Markets Covered: Antibacterial, Anti-Fungal, Anti-Viral
Companies Mentioned: Galderma (Nestle Skin Health), Johnson & Johnson, AbbVie, GlaxosmithKline, and Pfizer
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Dermatology Drugs Indicators Comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Products
Products
Antibacterial, Anti-Fungal, Anti-Viral
Companies
Galderma (Nestle Skin Health), Johnson & Johnson, AbbVie, GlaxosmithKline, and Pfizer
Table of Contents
Table of Contents
1. Dermatology Drugs Market Characteristics;
2. Dermatology Drugs Market Size And Growth;
2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;
3. Pestle Analysis;
3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;
4. Dermatology Drugs Market Customer Information;
5. Dermatology Drugs Market Segmentation;
5.1. Global Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 5.2. Global Dermatology Drugs Market, 2012-2020, Historic And Forecast, By Segment; 5.3 Global Dermatology Drugs Market Trends And Strategies;
6. Dermatology Drugs Market Regional And Country Analysis;
6.1. Global Dermatology Drugs Market, 2016, By Region; 6.2. Global Dermatology Drugs Market, 2012-2020, Historic And Forecast, By Region; 6.3. Dermatology Drugs Market, 2016, By Country; 6.4. Dermatology Drugs Market, 2012-2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7. Global Pharmaceutical Market Segments, 2016, By Country; 6.8. Global Pharmaceutical Drugs Market Segments, 2016, By Country;
7. Global Dermatology Drugs Market Comparison With Macro Economic Factors;
7.1. Dermatology Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Dermatology Drugs Expenditure, Global;
8. Dermatology Drugs Market Comparison With Macro Economic Factors Across Countries;
8.1. Dermatology Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Dermatology Drugs Expenditure, By Country;
9. Dermatology Drugs Market Comparison With Industry Metrics;
9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Dermatology Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Dermatology Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Dermatology Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Dermatology Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Dermatitis, 2014, By Country;
10. Asia-Pacific Dermatology Drugs Market;
10.1.1. Asia-Pacific Dermatology Drugs Market Overview; 10.1.2. Asia-Pacific Dermatology Drugs Historic Market, 2012-2016; 10.1.3. Asia-Pacific Dermatology Drugs Forecast Market, 2016-2020; 10.1.4. Asia-Pacific Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 10.2. Asia-Pacific Dermatology Drugs Market: Country Analysis; 10.3. China Dermatology Drugs Market; 10.3.1. China Dermatology Drugs Market Overview; 10.3.2. China Dermatology Drugs Historic Market, 2012-2016; 10.3.3. China Dermatology Drugs Forecast Market, 2016-2020; 10.3.4. China Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 10.3.5. China Dermatology Drugs Percentage Of GDP, 2012-2020; 10.3.6. China Per Capita Average Dermatology Drugs Expenditure, 2012-2020; 10.4. India Dermatology Drugs Market; 10.4.1. India Dermatology Drugs Market Overview; 10.4.2. India Dermatology Drugs Historic Market, 2012-2016; 10.4.3. India Dermatology Drugs Forecast Market, 2016-2020; 10.4.4. India Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 10.4.5. India Dermatology Drugs Percentage Of GDP, 2012-2020; 10.4.6. India Per Capita Average Dermatology Drugs Expenditure, 2012-2020; 10.5. Japan Dermatology Drugs Market; 10.5.1. Japan Dermatology Drugs Market Overview; 10.5.2. Japan Dermatology Drugs Historic Market, 2012-2016; 10.5.3. Japan Dermatology Drugs Forecast Market, 2016-2020; 10.5.4. Japan Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 10.5.5. Japan Dermatology Drugs Percentage Of GDP, 2012-2020; 10.5.6. Japan Per Capita Average Dermatology Drugs Expenditure, 2012-2020; 10.6. Australia Dermatology Drugs Market; 10.6.1. Australia Dermatology Drugs Historic Market, 2012-2016; 10.6.2. Australia Dermatology Drugs Forecast Market, 2016-2020; 10.6.3. Australia Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 10.6.4. Australia Dermatology Drugs Percentage Of GDP, 2012-2020; 10.6.5. Australia Per Capita Average Dermatology Drugs Expenditure, 2012-2020;
11. Western Europe Dermatology Drugs Market;
11.1.1. Western Europe Dermatology Drugs Market Overview; 11.1.2. Western Europe Dermatology Drugs Historic Market, 2012-2016; 11.1.3. Western Europe Dermatology Drugs Forecast Market, 2016-2020; 11.1.4. Western Europe Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 11.2. Western Europe Dermatology Drugs Market: Country Analysis; 11.3. UK Dermatology Drugs Market; 11.3.1. UK Dermatology Drugs Market Overview; 11.3.2. UK Dermatology Drugs Historic Market, 2012-2016; 11.3.3. UK Dermatology Drugs Forecast Market, 2016-2020; 11.3.4. UK Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 11.3.5. UK Dermatology Drugs Percentage Of GDP, 2012-2020; 11.3.6. UK Per Capita Average Dermatology Drugs Expenditure, 2012-2020; 11.4. Germany Dermatology Drugs Market; 11.4.1. Germany Dermatology Drugs Historic Market, 2012-2016; 11.4.2. Germany Dermatology Drugs Forecast Market, 2016-2020; 11.4.3. Germany Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 11.4.4 Germany Dermatology Drugs Percentage Of GDP, 2012-2020; 11.4.5 Germany Per Capita Average Dermatology Drugs Expenditure, 2012-2020; 11.5 France Dermatology Drugs Market; 11.5.1 France Dermatology Drugs Historic Market, 2012-2016; 11.5.2 France Dermatology Drugs Forecast Market, 2016-2020; 11.5.3 France Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 11.5.4 France Dermatology Drugs Percentage Of GDP, 2012-2020; 11.5.5 France Per Capita Average Dermatology Drugs Expenditure, 2012-2020; 11.6. Italy Dermatology Drugs Market; 11.6.1. Italy Dermatology Drugs Historic Market, 2012-2016; 11.6.2. Italy Dermatology Drugs Forecast Market, 2016-2020; 11.6.3. Italy Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 11.6.4. Italy Dermatology Drugs Percentage Of GDP, 2012-2020; 11.6.5. Italy Per Capita Average Dermatology Drugs Expenditure, 2012-2020; 11.7. Spain Dermatology Drugs Market; 11.7.1. Spain Dermatology Drugs Historic Market, 2012-2016; 11.7.2. Spain Dermatology Drugs Forecast Market, 2016-2020; 11.7.3. Spain Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 11.7.4. Spain Dermatology Drugs Percentage Of GDP, 2012-2020; 11.7.5. Spain Per Capita Average Dermatology Drugs Expenditure, 2012-2020;
12. Eastern Europe Dermatology Drugs Market;
12.1.1. Eastern Europe Dermatology Drugs Market Overview; 12.1.2. Eastern Europe Dermatology Drugs Historic Market, 2012-2016; 12.1.3. Eastern Europe Dermatology Drugs Forecast Market, 2016-2020; 12.1.4 Eastern Europe Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 12.2. Eastern Europe Dermatology Drugs Market: Country Analysis; 12.3. Russia Dermatology Drugs Market; 12.3.1. Russia Dermatology Drugs Historic Market, 2012-2016; 12.3.2. Russia Dermatology Drugs Forecast Market, 2016-2020; 12.3.3. Russia Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 12.3.4. Russia Dermatology Drugs Percentage Of GDP, 2012-2020; 12.3.5. Russia Per Capita Average Dermatology Drugs Expenditure, 2012-2020;
13. North America Dermatology Drugs Market;
13.1.1. North America Dermatology Drugs Market Overview; 13.1.2. North America Dermatology Drugs Historic Market, 2012-2016; 13.1.3. North America Dermatology Drugs Forecast Market, 2016-2020; 13.1.4. North America Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 13.2. North America Dermatology Drugs Market: Country Analysis; 13.3. USA Dermatology Drugs Market; 13.3.1. USA Dermatology Drugs Historic Market, 2012-2016; 13.3.1. USA Dermatology Drugs Historic Market, 2012-2016; 13.3.2. USA Dermatology Drugs Forecast Market, 2016-2020; 13.3.3 USA Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 13.3.4. USA Dermatology Drugs Percentage Of GDP, 2012-2020; 13.3.5. USA Per Capita Average Dermatology Drugs Expenditure, 2012-2020;
14. South America Dermatology Drugs Market;
14.1.1. South America Dermatology Drugs Market Overview; 14.1.2. South America Dermatology Drugs Historic Market, 2012-2016; 14.1.3. South America Dermatology Drugs Forecast Market, 2016-2020; 14.1.4. South America Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 14.2. South America Dermatology Drugs Market: Country Analysis; 14.3. Brazil Dermatology Drugs Market; 14.3.1. Brazil Dermatology Drugs Historic Market, 2012-2016; 14.3.2. Brazil Dermatology Drugs Forecast Market, 2016-2020; 14.3.3. Brazil Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 14.3.4. Brazil Dermatology Drugs Percentage Of GDP, 2012-2020; 14.3.5. Brazil Per Capita Average Dermatology Drugs Expenditure, 2012-2020;
15. Middle East Dermatology Drugs Market;
15.1.1. Middle East Dermatology Drugs Market Overview; 15.1.2. Middle East Dermatology Drugs Historic Market, 2012-2016; 15.1.3. Middle East Dermatology Drugs Forecast Market, 2016-2020; 15.1.4. Middle East Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral;
16. Africa Dermatology Drugs Market;
16.1.1. Africa Dermatology Drugs Market Overview; 16.1.2. Africa Dermatology Drugs Historic Market, 2012-2016; 16.1.3. Africa Dermatology Drugs Forecast Market, 2016-2020; 16.1.4. Africa Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral;
17. Dermatology Drugs Market Competitive Landscape;
17.1. Company Profiles; 17.2. Galderma (Nestle Skin Health); 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Johnson & Johnson; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Abbvie; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Glaxosmithkline; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Pfizer; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;
18. Key Mergers And Acquisitions In The Dermatology Drugs Market;
19. Market Background: Pharmaceutical Drugs Market;
19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2016, By Country; 19.2.4. Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country; 19.2.5. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;
20. Pharmaceuticals Industry Financial Margins;
21. Appendix;
21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer
List of Figure
Table 1: Global Dermatology Drugs Historic Market Growth
Table 2: Global Dermatology Drugs Forecast Market Growth
Table 3: Dermatology Drugs Market Segmentation
Table 4: Global Dermatology Drugs Market, 2016, By Segment
Table 5: Global Dermatology Drugs Market, 2012-2020, Historic And Forecast, By Segment
Table 6: Global Dermatology Drugs Market, 2016, By Region
Table 7: Global Dermatology Drugs Market, 2012-2020, Historic And Forecast, By Region
Table 8: Dermatology Drugs Market, 2016, By Country
Table 9: Dermatology Drugs Market, 2012-2020, Historic And Forecast, By Country
Table 10: Global Pharmaceutical Market Segments, 2016, By Region
Table 11: Global Pharmaceutical Drugs Market Segments, 2016, By Region
Table 12: Global Pharmaceutical Market Segments, 2016, By Country
Table 13: Global Pharmaceutical Drugs Market Segments, 2016, By Country
Table 14: Dermatology Drugs Market Size, Percentage Of GDP, Global
Table 15: Per Capita Average Dermatology Drugs Expenditure, Global
Table 16: Dermatology Drugs Market Comparison With Macro Economic Factors Across Countries
Table 17: Dermatology Drugs Market Size, Percentage Of GDP, By Country
Table 18: Per Capita Average Dermatology Drugs Expenditure, By Country
Table 19: Global Number Of Pharmacists, 2016, By Country
Table 20: Global Dermatology Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country
Table 21: Global Number Of Pharma Enterprises, 2016, By Country
Table 22: Global Dermatology Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country
Table 23: Global Average Spending On R&D/Product Development, 2016, By Country
Table 24: Global Dermatology Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country
Table 25: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Table 26: Global Dermatology Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Table 27: Prevalent Cases Of Dermatitis, 2014, By Country
Table 28: Asia-Pacific Dermatology Drugs Historic Market, 2012-2016
Table 29: Asia-Pacific Dermatology Drugs Forecast Market, 2016-2020
Table 30: Asia-Pacific Dermatology Drugs Market, 2016, By Segment
Table 31: China Dermatology Drugs Historic Market, 2012-2016
Table 32: China Dermatology Drugs Forecast Market, 2016-2020
Table 33: China Dermatology Drugs Market, 2016, By Segment
Table 34: China Dermatology Drugs Percentage Of GDP, 2012-2020
Table 35: China Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Table 36: India Dermatology Drugs Historic Market, 2012-2016
Table 37: India Dermatology Drugs Forecast Market, 2016-2020
Table 38: India Dermatology Drugs Market, 2016, By Segment
Table 39: India Dermatology Drugs Percentage Of GDP, 2012-2020
Table 40: India Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Table 41: Japan Dermatology Drugs Historic Market, 2012-2016
Table 42: Japan Dermatology Drugs Forecast Market, 2016-2020
Table 43: Japan Dermatology Drugs Market, 2016, By Segment
Table 44: Japan Dermatology Drugs Percentage Of GDP, 2012-2020
Table 45: Japan Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Table 46: Australia Dermatology Drugs Historic Market, 2012-2016
Table 47: Australia Dermatology Drugs Forecast Market, 2016-2020
Table 48: Australia Dermatology Drugs Market, 2016, By Segment
Table 49: Australia Dermatology Drugs Percentage Of GDP, 2012-2020
Table 50: Australia Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Table 51: Western Europe Dermatology Drugs Historic Market, 2012-2016
Table 52: Western Europe Dermatology Drugs Forecast Market, 2016-2020
Table 53: Western Europe Dermatology Drugs Market, 2016, By Segment
Table 54: UK Dermatology Drugs Historic Market, 2012-2016
Table 55: UK Dermatology Drugs Forecast Market, 2016-2020
Table 56: UK Dermatology Drugs Market, 2016, By Segment
Table 57: UK Dermatology Drugs Percentage Of GDP, 2012-2020
Table 58: UK Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Table 59: Germany Dermatology Drugs Historic Market, 2012-2016
Table 60: Germany Dermatology Drugs Forecast Market, 2016-2020
Table 61: Germany Dermatology Drugs Market, 2016, By Segment
Table 62: Germany Dermatology Drugs Percentage Of GDP, 2012-2020
Table 63: Germany Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Table 64: France Dermatology Drugs Historic Market, 2012-2016
Table 65: France Dermatology Drugs Forecast Market, 2016-2020
Table 66: France Dermatology Drugs Market, 2016, By Segment
Table 67: France Dermatology Drugs Percentage Of GDP, 2012-2020
Table 68: France Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Table 69: Italy Dermatology Drugs Historic Market, 2012-2016
Table 70: Italy Dermatology Drugs Forecast Market, 2016-2020
Table 71: Italy Dermatology Drugs Market, 2016, By Segment
Table 72: Italy Dermatology Drugs Percentage Of GDP, 2012-2020
Table 73: Italy Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Table 74: Spain Dermatology Drugs Historic Market, 2012-2016
Table 75: Spain Dermatology Drugs Forecast Market, 2016-2020
Table 76: Spain Dermatology Drugs Market, 2016, By Segment
Table 77: Spain Dermatology Drugs Percentage Of GDP, 2012-2020
Table 78: Spain Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Table 79: Eastern Europe Dermatology Drugs Historic Market, 2012-2016
Table 80: Eastern Europe Dermatology Drugs Forecast Market, 2016-2020
Table 81: Eastern Europe Dermatology Drugs Market, 2016, By Segment
Table 82: Russia Dermatology Drugs Historic Market, 2012-2016
Table 83: Russia Dermatology Drugs Forecast Market, 2016-2020
Table 84: Russia Dermatology Drugs Market, 2016, By Segment
Table 85: Russia Dermatology Drugs Percentage Of GDP, 2012-2020
Table 86: Russia Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Table 87: North America Dermatology Drugs Historic Market, 2012-2016
Table 88: North America Dermatology Drugs Forecast Market, 2016-2020
Table 89: North America Dermatology Drugs Market, 2016, By Segment
Table 90: USA Dermatology Drugs Historic Market, 2012-2016
Table 91: USA Dermatology Drugs Forecast Market, 2016-2020
Table 92: USA Dermatology Drugs Market, 2016, By Segment
Table 93: USA Dermatology Drugs Percentage Of GDP, 2012-2020
Table 94: USA Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Table 95: South America Dermatology Drugs Historic Market, 2012-2016
Table 96: South America Dermatology Drugs Forecast Market, 2016-2020
Table 97: South America Dermatology Drugs Market, 2016, By Segment
Table 98: Brazil Dermatology Drugs Historic Market, 2012-2016
Table 99: Brazil Dermatology Drugs Forecast Market, 2016-2020
Table 100: Brazil Dermatology Drugs Market, 2016, By Segment
Table 101: Brazil Dermatology Drugs Percentage Of GDP, 2012-2020
Table 102: Brazil Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Table 103: Middle East Dermatology Drugs Historic Market, 2012-2016
Table 104: Middle East Dermatology Drugs Forecast Market, 2016-2020
Table 105: Middle East Dermatology Drugs Market, 2016, By Segment
Table 106: Africa Dermatology Drugs Historic Market, 2012-2016
Table 107: Africa Dermatology Drugs Forecast Market, 2016-2020
Table 108: Africa Dermatology Drugs Market, 2016, By Segment
Table 109: Galderma (Nestle Skin Health) Financial Performance
Table 110: Johnson & Johnson Financial Performance
Table 111: Abbvie Financial Performance
Table 112: Glaxosmithkline Financial Performance
Table 113: Pfizer Financial Performance
Table 114: Pharmaceutical Drugs Market Historic Growth
Table 115: Pharmaceutical Drugs Market Forecast Growth
Table 116: Global Pharmaceutical Drugs Market, 2016, By Region
Table 117: Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region
Table 118: Pharmaceutical Drugs Market, 2016, By Country
Table 119: Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country
Table 120: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment
Table 121: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment
Table 122: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global
Table 123: Per Capita Average Pharmaceutical Drugs Expenditure, Global
Table 124: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries
Table 125: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country
Table 126: Per Capita Average Pharmaceutical Drugs Expenditure, By Country
Table 127: Pharmaceuticals Industry Financial Margins
List of Table
Figure 1: Global Dermatology Drugs Historic Market Growth
Figure 2: Global Dermatology Drugs Forecast Market Growth
Figure 3: Dermatology Drugs Market Segmentation
Figure 4: Global Dermatology Drugs Market, 2016, By Segment
Figure 5: Global Dermatology Drugs Market, 2012-2020, Historic And Forecast, By Segment
Figure 6: Global Dermatology Drugs Market, 2016, By Region
Figure 7: Global Dermatology Drugs Market, 2012-2020, Historic And Forecast, By Region
Figure 8: Dermatology Drugs Market, 2016, By Country
Figure 9: Dermatology Drugs Market, 2012-2020, Historic And Forecast, By Country
Figure 10: Global Pharmaceutical Market Segments, 2016, By Region
Figure 11: Global Pharmaceutical Drugs Market Segments, 2016, By Region
Figure 12: Global Pharmaceutical Market Segments, 2016, By Country
Figure 13: Global Pharmaceutical Drugs Market Segments, 2016, By Country
Figure 14: Dermatology Drugs Market Size, Percentage Of GDP, Global
Figure 15: Per Capita Average Dermatology Drugs Expenditure, Global
Figure 16: Dermatology Drugs Market Comparison With Macro Economic Factors Across Countries
Figure 17: Dermatology Drugs Market Size, Percentage Of GDP, By Country
Figure 18: Per Capita Average Dermatology Drugs Expenditure, By Country
Figure 19: Global Number Of Pharmacists, 2016, By Country
Figure 20: Global Dermatology Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country
Figure 21: Global Number Of Pharma Enterprises, 2016, By Country
Figure 22: Global Dermatology Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country
Figure 23: Global Average Spending On R&D/Product Development, 2016, By Country
Figure 24: Global Dermatology Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country
Figure 25: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Figure 26: Global Dermatology Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Figure 27: Prevalent Cases Of Dermatitis, 2014, By Country
Figure 28: Asia-Pacific Dermatology Drugs Historic Market, 2012-2016
Figure 29: Asia-Pacific Dermatology Drugs Forecast Market, 2016-2020
Figure 30: Asia-Pacific Dermatology Drugs Market, 2016, By Segment
Figure 31: China Dermatology Drugs Historic Market, 2012-2016
Figure 32: China Dermatology Drugs Forecast Market, 2016-2020
Figure 33: China Dermatology Drugs Market, 2016, By Segment
Figure 34: China Dermatology Drugs Percentage Of GDP, 2012-2020
Figure 35: China Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Figure 36: India Dermatology Drugs Historic Market, 2012-2016
Figure 37: India Dermatology Drugs Forecast Market, 2016-2020
Figure 38: India Dermatology Drugs Market, 2016, By Segment
Figure 39: India Dermatology Drugs Percentage Of GDP, 2012-2020
Figure 40: India Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Figure 41: Japan Dermatology Drugs Historic Market, 2012-2016
Figure 42: Japan Dermatology Drugs Forecast Market, 2016-2020
Figure 43: Japan Dermatology Drugs Market, 2016, By Segment
Figure 44: Japan Dermatology Drugs Percentage Of GDP, 2012-2020
Figure 45: Japan Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Figure 46: Australia Dermatology Drugs Historic Market, 2012-2016
Figure 47: Australia Dermatology Drugs Forecast Market, 2016-2020
Figure 48: Australia Dermatology Drugs Market, 2016, By Segment
Figure 49: Australia Dermatology Drugs Percentage Of GDP, 2012-2020
Figure 50: Australia Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Figure 51: Western Europe Dermatology Drugs Historic Market, 2012-2016
Figure 52: Western Europe Dermatology Drugs Forecast Market, 2016-2020
Figure 53: Western Europe Dermatology Drugs Market, 2016, By Segment
Figure 54: UK Dermatology Drugs Historic Market, 2012-2016
Figure 55: UK Dermatology Drugs Forecast Market, 2016-2020
Figure 56: UK Dermatology Drugs Market, 2016, By Segment
Figure 57: UK Dermatology Drugs Percentage Of GDP, 2012-2020
Figure 58: UK Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Figure 59: Germany Dermatology Drugs Historic Market, 2012-2016
Figure 60: Germany Dermatology Drugs Forecast Market, 2016-2020
Figure 61: Germany Dermatology Drugs Market, 2016, By Segment
Figure 62: Germany Dermatology Drugs Percentage Of GDP, 2012-2020
Figure 63: Germany Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Figure 64: France Dermatology Drugs Historic Market, 2012-2016
Figure 65: France Dermatology Drugs Forecast Market, 2016-2020
Figure 66: France Dermatology Drugs Market, 2016, By Segment
Figure 67: France Dermatology Drugs Percentage Of GDP, 2012-2020
Figure 68: France Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Figure 69: Italy Dermatology Drugs Historic Market, 2012-2016
Figure 70: Italy Dermatology Drugs Forecast Market, 2016-2020
Figure 71: Italy Dermatology Drugs Market, 2016, By Segment
Figure 72: Italy Dermatology Drugs Percentage Of GDP, 2012-2020
Figure 73: Italy Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Figure 74: Spain Dermatology Drugs Historic Market, 2012-2016
Figure 75: Spain Dermatology Drugs Forecast Market, 2016-2020
Figure 76: Spain Dermatology Drugs Market, 2016, By Segment
Figure 77: Spain Dermatology Drugs Percentage Of GDP, 2012-2020
Figure 78: Spain Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Figure 79: Eastern Europe Dermatology Drugs Historic Market, 2012-2016
Figure 80: Eastern Europe Dermatology Drugs Forecast Market, 2016-2020
Figure 81: Eastern Europe Dermatology Drugs Market, 2016, By Segment
Figure 82: Russia Dermatology Drugs Historic Market, 2012-2016
Figure 83: Russia Dermatology Drugs Forecast Market, 2016-2020
Figure 84: Russia Dermatology Drugs Market, 2016, By Segment
Figure 85: Russia Dermatology Drugs Percentage Of GDP, 2012-2020
Figure 86: Russia Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Figure 87: North America Dermatology Drugs Historic Market, 2012-2016
Figure 88: North America Dermatology Drugs Forecast Market, 2016-2020
Figure 89: North America Dermatology Drugs Market, 2016, By Segment
Figure 90: USA Dermatology Drugs Historic Market, 2012-2016
Figure 91: USA Dermatology Drugs Forecast Market, 2016-2020
Figure 92: USA Dermatology Drugs Market, 2016, By Segment
Figure 93: USA Dermatology Drugs Percentage Of GDP, 2012-2020
Figure 94: USA Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Figure 95: South America Dermatology Drugs Historic Market, 2012-2016
Figure 96: South America Dermatology Drugs Forecast Market, 2016-2020
Figure 97: South America Dermatology Drugs Market, 2016, By Segment
Figure 98: Brazil Dermatology Drugs Historic Market, 2012-2016
Figure 99: Brazil Dermatology Drugs Forecast Market, 2016-2020
Figure 100: Brazil Dermatology Drugs Market, 2016, By Segment
Figure 101: Brazil Dermatology Drugs Percentage Of GDP, 2012-2020
Figure 102: Brazil Per Capita Average Dermatology Drugs Expenditure, 2012-2020
Figure 103: Middle East Dermatology Drugs Historic Market, 2012-2016
Figure 104: Middle East Dermatology Drugs Forecast Market, 2016-2020
Figure 105: Middle East Dermatology Drugs Market, 2016, By Segment
Figure 106: Africa Dermatology Drugs Historic Market, 2012-2016
Figure 107: Africa Dermatology Drugs Forecast Market, 2016-2020
Figure 108: Africa Dermatology Drugs Market, 2016, By Segment
Figure 109: Galderma (Nestle Skin Health) Financial Performance
Figure 110: Johnson & Johnson Financial Performance
Figure 111: Abbvie Financial Performance
Figure 112: Glaxosmithkline Financial Performance
Figure 113: Pfizer Financial Performance
Figure 114: Pharmaceutical Drugs Market Historic Growth
Figure 115: Pharmaceutical Drugs Market Forecast Growth
Figure 116: Global Pharmaceutical Drugs Market, 2016, By Region
Figure 117: Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region
Figure 118: Pharmaceutical Drugs Market, 2016, By Country
Figure 119: Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country
Figure 120: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment
Figure 121: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment
Figure 122: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global
Figure 123: Per Capita Average Pharmaceutical Drugs Expenditure, Global
Figure 124: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries
Figure 125: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country
Figure 126: Per Capita Average Pharmaceutical Drugs Expenditure, By Country
Figure 127: Pharmaceuticals Industry Financial Margins
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.